HSBC Securities upgraded Labcorp Holdings Inc. from Hold to Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2025 | $260.00 | Buy → Hold | HSBC Securities |
| 4/2/2025 | $276.00 | Buy | Redburn Atlantic |
| 3/4/2025 | $250.00 → $300.00 | Neutral → Buy | Citigroup |
| 1/7/2025 | $260.00 → $265.00 | In-line → Outperform | Evercore ISI |
| 12/10/2024 | $265.00 → $275.00 | Buy | Jefferies |
| 10/30/2024 | Hold → Buy | HSBC Securities | |
| 10/1/2024 | $235.00 | Neutral | Piper Sandler |
| 3/25/2024 | $250.00 | Hold → Buy | Argus |
Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of Alzheimer's disease through early detection of the amyloid plaques associated with the disease in appropriate patients. Developed by Fujirebio Diagnostics, Inc., the test is now available nationwide through Labcorp.
Test Finder interprets provider questions in context to deliver curated, clinically relevant results, going beyond traditional search Developed in collaboration with Amazon Web Services, Test Finder is now available on Labcorp.com BURLINGTON, N.C., July 30, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder, a first-of-its-kind generative AI tool developed with Amazon Web Services (AWS). Designed to simplify lab test selection, Test Finder enables healthcare providers to ask questions or describe conditions in plain language and receive curated test recommendations—enhancing the user experienc
First-and-only test of its kind approved under new European Union regulations expands access to personalized cancer care for patients across the EU BURLINGTON, N.C., July 29, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today PGDx elio™ tissue complete has been CE-marked under the European Union's (EU) new In Vitro Diagnostic Regulation (IVDR). It is now the first and only test of its kind in the EU CE-marked for comprehensive solid tumor profiling. This marks a significant milestone in expanding access to personalized treatment options for the approximately 2.7 million people diagnosed with cancer every year in the EU
144 - LABCORP HOLDINGS INC. (0000920148) (Subject)
10-Q - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00
Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00
Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as
SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company's continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform. Aicher's expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executiv
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.
Raises Full-Year Guidance Financial results from Operations for second quarter 2025 versus second quarter 2024:Revenue: $3.53 billion versus $3.22 billionDiluted EPS: $2.84 versus $2.43Adjusted EPS: $4.35 versus $3.94Raised Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue guidance narrowed to 7.5% to 8.6%; midpoint raised by 70 basis pointsAdjusted EPS range narrowed to $16.05 to $16.50; midpoint raised by $0.23Free Cash Flow range of $1.13 billion to $1.28 billion; midpoint raised by $25 millionBroadened our partnerships with hospitals, health systems and regional/local labs and enhanced access to comprehensive testing and laboratory servicesIntroduced several new tests
BURLINGTON, N.C., July 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 11, 2025, to stockholders of record as of the close of business on August 28, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and
BURLINGTON, N.C., June 26, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2025 before the market opens on Thursday, July 24, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participan
SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)
SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)
SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)